Skip to main content
ConductScienceScienceDex
NIH funding notice RFA-HD-14-031

Discovery of Molecular Targets for Pregnancy-Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (SBIR) (R43/R44)

Closed on February 27, 2014.

Posted
November 7, 2013
Close date
February 27, 2014
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $218,009 in first-year total cost, median $218,009.

Most frequent study sections

  1. Special Emphasis Panel[ZHD1 DRG-H (50)]1

Most frequent institutions

  1. AGGAMIN PHARMACEUTICALS, LLC1
Competing awards under RFA-HD-14-031 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2014Development of a Novel Biologic to Treat Preeclampsia1R43HD082657-01TAN, ADELENEAGGAMIN PHARMACEUTICALS, LLC, NY$218,009ZHD1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

Start your CVHow the NIH biosketch works
RFA-HD-14-031: Discovery of Molecular Targets for Pregnancy-Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (SBIR) (R43/R44) | ScienceDex | ConductScience